Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy
Details
Publication Year 2020-11-17,Volume 50,Issue #12,Page 1871-1884
Journal Title
Eur J Immunol
Publication Type
Journal Article
Abstract
The mutational landscape of human cancers is highly complex. While next generation sequencing aims to comprehensively catalogue somatic alterations in tumor cells, it fails to delineate driver from passenger mutations. Functional genomic approaches, particularly CRISPR/Cas9, enable both gene discovery, and annotation of gene function. Indeed, recent CRISPR/Cas9 technologies have flourished with the development of more sophisticated and versatile platforms capable of gene knockouts to high throughput genome wide editing of a single nucleotide base. With new platforms constantly emerging, it can be challenging to navigate what CRISPR tools are available and how they can be effectively applied to understand cancer biology. This review provides an overview of current and emerging CRISPR technologies and their power to model cancer and identify novel treatments. Specifically, how CRISPR screening approaches have been exploited to enhance immunotherapies through the identification of tumor intrinsic and extrinsic mechanisms to escape immune recognition will be discussed.
Publisher
Wiley
Keywords
Crispr; cancer; disease models; immunotherapy; screening
Research Division(s)
Blood Cells And Blood Cancer; Cancer Biology And Stem Cells
PubMed ID
33202035
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-02-01 12:07:26
Last Modified: 2021-03-02 11:18:05
An error has occurred. This application may no longer respond until reloaded. Reload 🗙